title: [Effectiveness and safety of fluticasone propionate in therapy of children suffering from asthma. Part II. Safety aspects of therapy with fluticasone propionate in asthmatic children].
abstract: Inhaled administration of glucocorticoid doesn't mean lack of systemic effects of drug. Bioavailability of steroid depends on oral absorption and absorption from respiratory system. In case of fluticasone propionate (FP) swallowed dose can be neglected because almost total (>99%) inactivation in liver during first pass. In second part of paper the most important safety parameters of therapy with FP are discussed, it means; influence on hypothalamic-pituitary-adrenal axis, growth and bone metabolism. Interpretation of potential side effects should differentiate between abnormal value of laboratory test and clinically important symptoms. Adrenal suppression depends on dose of FP and was found even after low dose (about 200 microg per day), but clinical value of this findings is unknown. Prolonged administration of high doses can suppress hypothalamic-pituitary-adrenal axis; exceptionally, it can induce adrenal insufficiency. Recommended doses of FP given 1 to 2 years doesn't cause growth retardation. Long term studies on influence of drug on final height are needed. FP as other inhaled corticosteroids, may transiently alter bone metabolism. Till now there are no evidences that this drug, when prescribed appropriately in standard doses for asthma control, may decrease the bone mineral density or induce osteoporosis and may increase the risk of bone fractures in asthmatic children. Effective asthma control achieved with FP therapy permits normal activity and development of asthmatic children which prevails over exceptionally noticed side effects.
authors.affiliation: Zakład Immunologii Klinicznej Akademii Medycznej w Lublinie.
authors.forename: Małgorzta
authors.initials: M
authors.lastname: Bartkowiak-Emeryk
authors.forename: Anna
authors.initials: A
authors.lastname: Breborowicz
authors.forename: Andrzej
authors.initials: A
authors.lastname: Emeryk
authors.forename: Marek
authors.initials: M
authors.lastname: Kulus
authors.forename: Ryszard
authors.initials: R
authors.lastname: Kurzawa
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Lis
authors.forename: Henryk
authors.initials: H
authors.lastname: Mazurek
authors.forename: Marek
authors.initials: M
authors.lastname: Niedziela
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000367:Age Factors; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy* / Q000517:prevention & control; D015519:Bone Density / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D000068298:Fluticasone; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone